Cabozantinib for advanced liver cancer after first-line immunotherapy
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests the drug cabozantinib (a pill that stops cancer growth) for people whose liver cancer has progressed after standard first-line immunotherapy. The goal is to see if it can slow down or shrink the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed diagnosis of liver cancer (hepatocellular carcinoma).
- Cancer grew during or after your first treatment with immunotherapy combinations (either Tecentriq + Avastin or Imfinzi + Imjudo).
- Tumors cannot be removed by surgery or treated with local therapies like ablation or embolization.
- You must be generally active and able to care for yourself (ECOG 0 or 1).
- Your liver function must be relatively preserved (Child-Pugh class A).
- No active hepatitis B or C infections (or they must be well-controlled).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two immunotherapy drugs (IBI310 and sintilimab) as a first treatment for advanced liver cancer that cannot be removed by surgery. It aims to see if this combination is safe and works better than current options.
This trial tests a new combination of chemotherapy (FOLFOX) plus atezolizumab and bevacizumab for people with advanced liver cancer that has grown after having atezolizumab and bevacizumab alone. The goal is to see if adding chemo helps stop the cancer from growing further.
This trial combines three medications—an immunotherapy (atezolizumab), a drug that blocks blood vessel growth (bevacizumab), and one that reduces inflammation (tocilizumab)—to see if they work together against advanced liver cancer. The goal is to slow cancer growth and possibly shrink the tumor.
This study looks at how well immunotherapy combinations work as the first treatment for advanced liver cancer that can't be surgically removed. It will track real-world patients to see how safe and effective these treatments are.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy pill (regorafenib) for people with advanced liver cancer that has progressed after first-line treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests a new combination of two immunotherapy drugs plus a targeted therapy and a procedure called TACE (which blocks the blood supply to the tumor) for people with advanced liver cancer. It aims to see if this combination can shrink tumors and help patients live longer.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.